KarXT + KarX-EC + KarXT + KarX-EC Matching Placebo
Phase 3Recruiting 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Irritability Associated With Autism Spectrum Disorder
Conditions
Irritability Associated With Autism Spectrum Disorder
Trial Timeline
Feb 27, 2026 → Jul 5, 2029
NCT ID
NCT07284745About KarXT + KarX-EC + KarXT + KarX-EC Matching Placebo
KarXT + KarX-EC + KarXT + KarX-EC Matching Placebo is a phase 3 stage product being developed by Bristol Myers Squibb for Irritability Associated With Autism Spectrum Disorder. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07284745. Target conditions include Irritability Associated With Autism Spectrum Disorder.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07285798 | Phase 3 | Recruiting |
| NCT07284745 | Phase 3 | Recruiting |
Competing Products
7 competing products in Irritability Associated With Autism Spectrum Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| KarXT + KarX-EC + KarXT + KarX-EC Matching Placebo | Bristol Myers Squibb | Phase 3 | 76 |
| Aripiprazole + Placebo | Bristol Myers Squibb | Approved | 84 |
| Brexpiprazole + Placebo | Lundbeck | Phase 3 | 74 |
| Brexpiprazole | Lundbeck | Phase 3 | 74 |
| JZP541 | Jazz Pharmaceuticals | Phase 2 | 49 |
| Pimavanserin | Acadia Pharmaceuticals | Phase 2/3 | 60 |
| Pimavanserin + Placebo | Acadia Pharmaceuticals | Phase 2/3 | 60 |